News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2013

Epigenomics: US study suggests blood-based Septin9 CRC screening could save lives and be health-economically beneficial

22.07.2013 | 130722_Press_release_Epigenomics_AG_Ladabaum_study CRC screening with blood-based Septin9 tests has potential to improve screening uptake and adherence rates Septin9 testing could decrease colorectal cancer (CRC) incidence by 41% and CRC mortality by 61% at optimal screening uptake rates Septin9 based screening shown to be cost-effective over no screening

Read more

Epigenomics Establishes American Depositary Receipt (ADR) Program

09.07.2013 | 130709_Press_release_Epigenomics_AG_ADR Epigenomics ADRs can be traded on US over-the-counter (OTC) market effective as of July 9, 2013 ADR ticker symbol EPGNY 1 ADR represents 5 ordinary company shares Berlin, Germany, and U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced that the Company has established a […]

Read more

Results of Comparative Study between Epigenomics Epi proColon® and FIT to be Presented at Digestive Disease Week

15.05.2013 | 130515_Press_release_Epigenomics_AG_DDW Berlin, Germany, and U.S.A., – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced that results of the head-to-head comparative study between its blood-based colorectal cancer (CRC) detection test Epi proColon® and fecal immunochemical testing (FIT) will be presented at a workshop of the WEO (World Endoscopy Organization) […]

Read more

Epigenomics AG Announces Q1 2013 Financial Results and Reports on Operational Highlights

08.05.2013 | 130508_Press_release_Epigenomics_AG_Q1_2013_Financial_Results Berlin, Germany, and, U.S.A., – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced its financial results for the first quarter ending March 31, 2013. U.S. Food and Drug Administration (FDA) accepted Premarket Approval (PMA) submission for Epi proColon® and granted priority review status Revenue Q1 2013 increased […]

Read more

Epigenomics AG: Dr. Uwe Staub Appointed to the Executive Board

03.04.2013 | 130403_Press_release_Epigenomics_AG_Dr__Uwe_Staub_COO Berlin, Germany, and U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced that Dr. Uwe Staub, Chief Operating Officer (COO) of the Company, has been appointed to the Executive Board, effective April 1, 2013. He will join the board as a second member next to […]

Read more

Epigenomics AG Reports Results for the Financial Year Ended 31 December 2012

– PMA application for Epi proColon® accepted and priority review status – Non-inferiority of Epi proColon® to FIT for sensitivity shown in comparison study – Significant cost savings implemented; EUR 5.0 million raised at the beginning of 2013 21.03.2013 | 130321_Press_release_results_FY_2012 Berlin, Germany and U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer […]

Read more